EGFR and non-small cell lung carcinoma: Gefitinib-resistant NSCLC cell lines (H157 and H1299) treated with a combination of curcumin and gefitinib diminish the activity of EGFR through repression of Sp1, which in turn blocks the interaction of Sp1 with HDAC-1.